We demonstrated that these drugs downregulate MCL1 activity via distinct mechanisms and synergize significantly with the BCLXL inhibitor, leading to enhanced anti-tumor activity with tolerable toxicity in preclinical GC models. The gene discussed is BCL2L1; the disease is neoplasm.